HOME >> BIOLOGY >> NEWS
Trio of leukemias share a single mutation

Three leukemias that affect as many as 100,000 people in the United States are all caused by acquired mutations that alter a specific enzyme controlling blood cell proliferation, according to new studies by Howard Hughes Medical Institute (HHMI) researchers.

Identifying the genetic malfunction that causes these disorders raises the hope that researchers may be able to devise a targeted therapy, just as they have done for chronic myelogenous leukemia (CML), which is presently treated with Gleevec. The three leukemias that share a common genetic cause are polycythemia vera (PV), essential thrombocythemia (ET) and myeloid metaplasia with myelofibrosis (MMM).

The research team, which was led by Gary Gilliland, an HHMI investigator at Brigham and Women's Hospital and Harvard Medical School, published its findings on March 24, 2005, in an immediate early publication in the journal Cancer Cell. Gilliland and Stephanie Lee of the Dana-Farber Cancer Institute, and co-first authors Ross Levine and Martha Wadleigh, collaborated with researchers from the University of Leuven - Flanders Interuniversity Institute for Biotechnology in Belgium, University Hospital of Ulm in Germany, the Broad Institute, and the Mayo Clinic.

According to Gilliland, the researchers analyzed the blood of patients with the three leukemias for a defect that permanently activated a particular type of enzyme called a tyrosine kinase. Tyrosine kinases are cellular switches that control an array of cellular processes. The researchers concentrated on the enzymes because activated tyrosine kinases had been shown to cause other similar myeloproliferative diseases such as CML, he said. Also, in earlier work, Gilliland and his colleagues had isolated the mutated gene that produces the activated tyrosine kinase responsible for the myeloproliferative disease hypereosinophilic syndrome.

"The three disorders that we studied were the last of these diseases whose causes had not yet been discovered,
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
24-Mar-2005


Page: 1 2 3 4

Related biology news :

1. Researchers discover a stem-cell switch lurking within leukemias
2. 20 Kentucky firms share $1.9 million from state to match federal SBIR-STTR awards
3. Where is the proton? Yale scientists discover footprints of shared protons
4. Scripps research study shows humans and plants share common regulatory pathway
5. Genes and groups of genes commonly shared between species, studies show
6. Family members with MS likely to share onset age, but not disease severity
7. Public shares views on environmental, health and safety research needs for nanoscale materials
8. Green plants share bacterial toxin
9. American Andrew Z. Fire shares Nobel Prize for discovering RNAi
10. Telomere expert Carol Greider shares 2006 Albert Lasker Award for Basic Medical Research
11. Ocean seep mollusks may share evolutionary history with other deep-sea creatures

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/31/2020)... (PRWEB) , ... July 30, 2020 , ... ... Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical ... this project is to develop, optimize, and scale-up a highly efficient mammalian cell ...
(Date:7/22/2020)... ... July 21, 2020 , ... ... in technology and compliance, announces a new solution to manage regulated workloads on ... layer of their technology stack complies with FDA and global regulations. USDM's new ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... , ... The SDX® Respiratory Gating System , trusted ... its 20th anniversary of worldwide use. Introduced in the US over the past ... of Pennsylvania, University of Michigan, University of Maryland, University of California San Francisco—and ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to ... Bioactives. “It’s the only technology of its kind on the market and we were ... with the protective capacity of traditional cultured ingredients, creating a natural way to extend ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... that Massachusetts Institute of Technology (MIT) has expanded the company’s exclusive license ... to move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 ...
(Date:7/7/2020)... ... July 06, 2020 , ... ... from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, ... has hosted an elite awards program, highlighting outstanding examples of how technology innovations ...
Breaking Biology Technology:
Cached News: